ライフサイエンスコーパス: cardiac glycoside

1 similar to those of digoxin, a plant-derived cardiac glycoside.

2 been blocked by endogenous ouabain or other cardiac glycosides.

3 that potently inhibits hERG trafficking are cardiac glycosides.

4 tic uptake transporter for such compounds as cardiac glycosides.

5 alpha-sugar and lactone ring moieties of the cardiac glycosides.

6 the hypothesis for a role of the endogenous cardiac glycosides.

7 steroid derivative closely related to plant cardiac glycosides.

8 ncluding Na/K-ATPase, the putative target of cardiac glycosides.

9 to have homologies to the steroidal core of cardiac glycosides.

10 Na,K-ATPase is responsible for the effect of cardiac glycosides.

11 verse compounds, and has a high affinity for cardiac glycosides.

12 450s differentially affect hepatic uptake of cardiac glycosides.

13 by q(gamma) charge following treatment with cardiac glycosides.

14 d Oatp2 (Slc21a5), mediate hepatic uptake of cardiac glycosides.

15 gs that PB and PCN enhance hepatic uptake of cardiac glycosides.

16 Among them were several cardiac glycosides, a class of cardenolides historically

17 The features of cardiac glycoside action thus parallel those of other ag

18 yme activity following inhibition by various cardiac glycosides and their aglycones at different pH v

19 One group consists mainly of cardiac glycosides and will be the subject of another st

20 ructurally related to the digitalis class of cardiac glycosides, and its putative target is the Na(+)

21 ,000 known bioactive compounds revealed that cardiac glycosides, antagonists of Na(+),K(+)-ATPase, in

22 Certain other cardiac glycosides are also active but with much less po

23 Digitoxin and other cardiac glycosides are important, centuries-old drugs fo

24 ether these hitherto unrecognized effects of cardiac glycosides are obtained in the intact heart and

25 Cardiac glycosides are used clinically to increase contr

26 cells) when compared with concentrations of cardiac glycosides (arrhythmogenic index, 4.10; n = 8 ce

27 Additional adjustment for baseline use of cardiac glycosides attenuated the association between AF

28 Thus, a link between the cardiac glycoside binding site and the cation transport

29 together these results demonstrate that the cardiac glycoside binding site of the alpha isoforms of

30 This result indicates that the cardiac glycoside binding site of the alpha1 isoform can

31 This finding demonstrates that the cardiac glycoside binding site of the Na,K-ATPase plays

32 at Trp-H100, which is part of the antibody's cardiac glycoside binding site, is a major determinant o

33 Tyr residue (Tyr-H100) which is part of the cardiac glycoside binding site, located approximately 10

34 y transfer to AO is likely to be part of the cardiac glycoside binding site.

35 r domain that constitutes a core part of the cardiac glycoside binding site.

36 relationship between receptor structure and cardiac glycoside binding.

37 dynamically by a mechanism that utilizes the cardiac glycoside-binding site and an endogenous ligand(

38 ite and an endogenous ligand(s) and that its cardiac glycoside-binding site can play a physiological

39 The physiological significance of the cardiac glycoside-binding site on the Na,K-ATPase remain

40 f the Na,K-ATPase to investigate whether the cardiac glycoside-binding site plays any physiological r

41 erations perturb the interaction between the cardiac glycoside bufalin and the Na(+)/K(+)-ATPase.

42 oughput screening effort that identified the cardiac glycoside bufalin as a potent small-molecule inh

43 Severe cardiac glycoside cardiotoxicity after ingestion of yell

44 in belongs to a naturally occurring class of cardiac glycosides (CG); digitoxin is clinically approve

45 The cardiac glycosides (CGs) digoxin, digitoxin and ouabain,

46 The therapeutic use of cardiac glycosides (CGs), agents commonly used in treati

47 ly and functionally related compounds of the cardiac glycoside class and known inhibitors of Na(+)K(+

48 ns represent the major binding sites for the cardiac glycoside class of drugs.

49 ovide evidence that oleandrin, the principal cardiac glycoside component of PBI-05204, can quantitati

50 roids were investigated by comparing various cardiac glycoside compounds like ouabain, digoxin, digit

51 Other cardiac glycoside compounds tested also showed neuroprot

52 ing a high-content screen, we identified the cardiac glycoside convallatoxin as an effective compound

53 the extent to which high-affinity binding of cardiac glycosides correlates with their potency in inhi

54 rrors of hepatic metabolism and suggest that cardiac glycosides could provide an approach for reducin

55 A purified cardiac glycoside derived from the foxglove plant, digox

56 Oleandrin, a polyphenolic cardiac glycoside derived from the leaves of Nerium olea

57 igh affinity scFv antibody that binds to the cardiac glycoside digoxigenin.

58 ell-based reporter system, we identified the cardiac glycoside digoxin as a specific inhibitor of ROR

59 patients with chronic LV dysfunction is the cardiac glycoside digoxin.

60 pha3beta1 isoforms showed that the classical cardiac glycoside, digoxin, is partially alpha2-selectiv

61 focuses on the quantitative analysis of the cardiac glycoside drug digitoxin and its three main meta

62 of human cancer cells, is down-regulated by cardiac glycoside drugs digoxin and ouabain, potent inhi

63 Digitoxin and structurally related cardiac glycoside drugs potently block activation of the

64 This is the first report that cardiac glycoside drugs, by initiating the Src/MAPK sign

65 Cardiac glycosides exert a positive inotropic effect by

66 Here, we report 3 compounds in the cardiac glycoside family, ouabain, gitoxigenin, and digi

67 .8-48-fold increases in the I50 of different cardiac glycosides for inhibition of the Na,K-ATPase act

68 n derivatives explains beneficial effects of cardiac glycosides for treatment of heart failure and po

69 e increased capacity of the liver to extract cardiac glycosides from the plasma.

70 Cardiac glycosides have played a prominent role in the t

71 nd pharmacodynamics of different variants of cardiac glycosides identified the mechanism of inhibitio

72 Because the alpha1 isoform is sensitive to cardiac glycosides in humans, we developed mice in which

73 se findings support further investigation of cardiac glycosides in providing neuroprotection in the c

74 ibian muscle fibres following treatment with cardiac glycosides in the hypertonic gluconate-containin

75 The role of cardiac glycosides in treating patients with chronic hea

76 Here, we report that multiple cardiac glycosides, including digitoxin and digoxin, are

77 Eleven of these drugs were cardiac glycosides, including digoxin, ouabain, and pros

78 ls and, unpredictably, identified a group of cardiac glycosides, including ouabain and digoxin, as po

79 a divergent mechanistic relationship between cardiac glycoside-induced cytotoxicity and Na+/K+-ATPase

80 Cardiac glycoside-induced intracellular K(+) depletion c

81 Digoxin and other cardiac glycosides inhibit hypoxia-inducible factor-1 (H

82 this link suggests a possible mechanism for cardiac glycoside inhibition of the Na,K-ATPase, such th

83 Furthermore, ouabain, a cardiac glycoside inhibitor of the Na(+)/K(+)-ATPase, po

84 Our data suggest that cardiac glycosides interact with phosphorylated mediator

85 to explain the positive inotropic effect of cardiac glycosides invokes altered Na+-Ca2+ exchange act

86 Inhibition of Na,K-ATPase activity by cardiac glycosides is believed to be the major mechanism

87 ously that inhibition of hERG trafficking by cardiac glycosides is initiated via direct block of Na(+

88 Cardiac glycoside-mediated effects on NMD are dependent

89 We report the discovery that cardiac glycosides, natural products in clinical use for

90 he associations among breast cancer, AF, and cardiac glycosides need further investigation.

91 fer modest increases in the concentration of cardiac glycoside needed to produce 50% inhibition of ac

92 ibition of ATG-dependent phagocytosis by the cardiac glycoside neriifolin, an inhibitor of the Na(+),

93 uroprotective action in ischemic stroke, the cardiac glycoside neriifolin, and demonstrated that its

94 We postulated that increased uptake of cardiac glycosides observed after pretreatment of animal

95 Here, we report that the cardiac glycosides oleandrin, ouabain, and digoxin induc

96 ger is absolutely required for the effect of cardiac glycosides on Ca2+(i).

97 Effects of topically applied cardiac glycosides on intraocular pressure in rabbits ha

98 Thus, an existing cardiac glycoside or closely related compound could prov

99 ither indirectly after long-term exposure to cardiac glycosides or directly after exposure to gramici

100 over time and sensitive to inhibition by the cardiac glycoside ouabain, a specific inhibitor of the N

101 appears to be an isomer of the plant-derived cardiac glycoside ouabain, if not ouabain itself.

102 uabain (AO), a fluorescent derivative of the cardiac glycoside ouabain, to mAbs 26-10, 45-20, and 40-

103 Blocking Na+, K(+)-ATPase activity with cardiac glycosides (ouabain or strophanthidin, 1 mM) or

104 n of alpha3 using a low concentration of the cardiac glycoside, ouabain, resulted in a modest increas

105 Na,K-ATPase is specifically inhibited by the cardiac glycoside, ouabain.

106 drug-induced trafficking inhibition in which cardiac glycosides produce a [K(+)](i)-mediated conforma

107 We show that resistance to toxic cardiac glycosides produced by plants and bufonid toads

108 These results define the distribution of the cardiac glycoside receptor isoforms in the human heart a

109 ng between anthroylouabain (AO) bound to the cardiac glycoside receptor site on alpha and the carbohy

110 ion is negligible, indicating that the human cardiac glycoside receptors are alpha1beta1, alpha2beta1

111 We found that cardiac glycosides reduce the production of apolipoprote

112 revealed that the treatment of patients with cardiac glycosides reduced serum LDL-C levels.

113 nfused with Digibind to sequester endogenous cardiac glycoside(s) produced similar effects on both re

114 Cardiac glycosides such as ouabain and digoxin specifica

115 Na(+),K(+)-ATPase is inhibited by cardiac glycosides such as ouabain, and palytoxin, which

116 echanism by which digitoxin and other active cardiac glycosides, such as digoxin, exert system-wide a

117 The Na,K-ATPase contains a binding site for cardiac glycosides, such as ouabain, digoxin, and digito

118 Several studies also suggest that cardiac glycosides, such as ouabain, function by mechani

119 Our results define a novel activity for cardiac glycosides that could prove relevant to the trea

120 e the fact that the molecular target for the cardiac glycosides, the alpha-subunit of sarcolemmal Na+

121 Cardiac glycoside use was strongly associated with incid

122 s and inhibitory potencies of a series of 37 cardiac glycosides using radioligand binding and ATPase

123 Using a panel of cardiac glycoside variants, we assessed the structural e

124 pha2 isoform, which is normally sensitive to cardiac glycosides, was made resistant to these compound

125 Although the cardiac glycosides were identified in an evaluation of 2

126 strated that the proapoptotic effects of the cardiac glycosides were linked to their abilities to ind

127 d sample for measurement of electrolytes and cardiac glycosides were taken before treatment and at 12

128 iandrogen therapy, we identify Peruvoside, a cardiac glycoside, which can potently inhibit both andro

129 ansport activity is effectively inhibited by cardiac glycosides, which bind to the extracellular side